

RECEIVED
CENTRAL FAX CENTER

AUG 21 2006

Reply Under 37 CFR 1.116
Expedited Procedure
Technology Center 1624
Docket No. 53001AUSM1REMARKSStatus of Claims and Claim Amendments

Claims 11-14, 18 and 20-25 were pending in the application. Claims 11-14, 18 and 23-25 are allowed and claims 20-22, rejoined in the present Office Action, are rejected.

Claims 20-22 (Group VIII), which were cancelled in the response filed June 6, 2006, are again canceled, in view of the earlier restriction requirement, without prejudice to filing the subject matter of the claims in a continuing application. The claims now remaining in the application are claims 11-14, 18 and 23-25.

Rejection under 35 U.S.C. §112, 1st paragraph

Claims 20-22 have been rejected as failing to comply with the enablement requirement.


Response: While Applicants disagree with this rejection, in view of the cancellation, without prejudice, of claims 20-22 herein, it is believed that the rejection is now moot. It will be addressed when and if it is raised in a continuing application.

CONCLUSION

The Office Action dated 08/10/2006 has been carefully considered. It is believed that the amendments submitted herein and the above comments represent a complete response to the Examiner's rejections and place the present application in condition for allowance. Reconsideration is respectfully requested.

If the USPTO determines that any fees are due, the Commissioner is hereby authorized to charge deposit account 02-2117. However, this is not authorization to charge the issue fee.

Respectfully submitted,

Jacqueline S. Larson
Patent Attorney for Applicants
Registration No. 30279Date: Aug. 21, 2006Berlex Pharmaceuticals
Corporate Patents
2600 Hilltop Drive
Richmond, California 94804-0099
Phone: 510-669-4483
Fax: 510-262-7095
E-mail: jackie_larson@berlex.com